Maxcyte (MXCT) Liabilities and Shareholders Equity (2020 - 2026)

Maxcyte (MXCT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $194.5 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 15.43% year-over-year to $194.5 million in Q1 2026; TTM through Mar 2026 was $830.2 million, a 14.37% decrease from a year earlier, with the FY2025 full-year figure at $202.5 million, down 15.44% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $194.5 million, down from $202.5 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MXCT reached as high as $291.0 million in Q1 2022 and fell as low as $194.5 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $252.9 million across 5 years, with a median of $257.9 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity jumped 211.1% in 2022 and declined 15.44% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $286.7 million in 2022, then decreased by 6.41% to $268.3 million in 2023, then dropped by 10.74% to $239.5 million in 2024, then declined by 15.44% to $202.5 million in 2025, then retreated by 3.97% to $194.5 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $194.5 million in Q1 2026, $202.5 million in Q4 2025, and $213.5 million in Q3 2025.